Teva Pharmaceutical Industries (TEVJF) Change in Acquisitions & Divestments (2017 - 2025)

Teva Pharmaceutical Industries has disclosed Change in Acquisitions & Divestments across 8 years of filings, most recently posting $42.0 million for Q4 2025.

• Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $42.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $82.0 million (up 105.0% YoY) and the FY2025 annual result came in at $42.0 million, up 5.0% from the prior year.
• Change in Acquisitions & Divestments rose to $42.0 million in Q4 2025, from $40.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $107.0 million in Q2 2021 and troughed at $1.0 million in Q3 2022.
• A 4-year average of $36.9 million and a median of $40.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2021 — Change in Acquisitions & Divestments jumped 3466.67% — and 2022, when it tumbled 97.2%.
• Tracing TEVJF's Change in Acquisitions & Divestments over 4 years: stood at $19.0 million in 2021, then sank by 94.74% to $1.0 million in 2022, then surged by 3900.0% to $40.0 million in 2024, then climbed by 5.0% to $42.0 million in 2025.
• Business Quant data shows TEVJF's Change in Acquisitions & Divestments at $42.0 million in Q4 2025, $40.0 million in Q3 2024, and $1.0 million in Q3 2022.